Literature DB >> 22414001

Silencing thioredoxin induces liver cancer cell senescence under hypoxia.

Ti Zhang1, Heping Liu, Cihui Zhu, Katrina Briggs, Ya'an Kang, Jason A Fleming, Steven A Curley.   

Abstract

AIM: Although thioredoxin 1 (TXN) has pleiotropic cellular functions as a redox-sensitive protein, very little is known about its role in tumor survival and growth under hypoxia. MHCC97H hepatocellular carcinoma cells have a high metastatic potential and high thioredoxin expression levels compared with their parent cell line, MHCC97. Thus, we used this cell line to explore the functional connections between TXN and hypoxia.
METHODS: MHCC97H cells were cultured under normoxia and hypoxia for specific periods after nucleofection with TXN siRNA or control siRNA. We assessed the β-phenylethyl isothiocyanate (PEITC) sensitivity of the cells, cell proliferation, cell cycle and senescence, and DNA damage response by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, colony formation assays, flow cytometry, β-galactosidase staining, western blotting, and immunohistochemistry.
RESULTS: β-phenylethyl isothiocyanate treatment shifted reduced TXN to oxidized TXN in MHCC97H cells. Although silencing of TXN via siRNA had no effect on the PEITC sensitivity of the cells, it suppressed cell proliferation and colony formation under both normoxia and hypoxia. Under hypoxia, silencing TXN did not induce apoptosis but induced DNA damage response and cellular senescence.
CONCLUSIONS: High TXN levels in MHCC97H cells protect them from DNA damage and cellular senescence under hypoxia. Targeting TXN might enhance the chemotherapeutic effects of some DNA-damaging agents against hepatocellular carcinoma.
© 2012 The Japan Society of Hepatology.

Entities:  

Year:  2012        PMID: 22414001      PMCID: PMC3374013          DOI: 10.1111/j.1872-034X.2012.00973.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  19 in total

1.  Binding of chromatin-modifying activities to phosphorylated histone H2A at DNA damage sites.

Authors:  Jessica A Downs; Stéphane Allard; Olivier Jobin-Robitaille; Ali Javaheri; Andréanne Auger; Nathalie Bouchard; Stephen J Kron; Stephen P Jackson; Jacques Côté
Journal:  Mol Cell       Date:  2004-12-22       Impact factor: 17.970

2.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

Authors:  G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

3.  Significant role for p16INK4a in p53-independent telomere-directed senescence.

Authors:  Jacqueline J L Jacobs; Titia de Lange
Journal:  Curr Biol       Date:  2004-12-29       Impact factor: 10.834

4.  The in vivo distribution of oxidized and reduced thioredoxin in Escherichia coli.

Authors:  A Holmgren; M Fagerstedt
Journal:  J Biol Chem       Date:  1982-06-25       Impact factor: 5.157

5.  Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion.

Authors:  A R Farina; A Tacconelli; L Cappabianca; M P Masciulli; A Holmgren; G J Beckett; A Gulino; A R Mackay
Journal:  Eur J Biochem       Date:  2001-01

6.  Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.

Authors:  G Berrozpe; J Schaeffer; M A Peinado; F X Real; M Perucho
Journal:  Int J Cancer       Date:  1994-07-15       Impact factor: 7.396

7.  Thioredoxin regenerates proteins inactivated by oxidative stress in endothelial cells.

Authors:  M R Fernando; H Nanri; S Yoshitake; K Nagata-Kuno; S Minakami
Journal:  Eur J Biochem       Date:  1992-11-01

8.  Suppression of thioredoxin-1 induces premature senescence in normal human fibroblasts.

Authors:  Jennifer J Young; Asmita Patel; Priyamvada Rai
Journal:  Biochem Biophys Res Commun       Date:  2010-01-13       Impact factor: 3.575

9.  Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide.

Authors:  A Yokomizo; M Ono; H Nanri; Y Makino; T Ohga; M Wada; T Okamoto; J Yodoi; M Kuwano; K Kohno
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

10.  Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials.

Authors:  Shi-Jian Ding; Yan Li; Xiao-Xia Shao; Hu Zhou; Rong Zeng; Zhao-You Tang; Qi-Chang Xia
Journal:  Proteomics       Date:  2004-04       Impact factor: 3.984

View more
  3 in total

1.  Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection.

Authors:  Bin Yu; Han Liang; Qifa Ye; Yanfeng Wang
Journal:  J Gastrointest Surg       Date:  2020-03-03       Impact factor: 3.452

2.  Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.

Authors:  Zhigui Guo; Manqing Cao; Abin You; Junrong Gao; Hongyuan Zhou; Huikai Li; Yunlong Cui; Feng Fang; Wei Zhang; Tianqiang Song; Qiang Li; Xiaolin Zhu; Huichuan Sun; Ti Zhang
Journal:  Cancer Sci       Date:  2016-02-23       Impact factor: 6.716

3.  Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice.

Authors:  Pasupathi Sundaramoorthy; Qinhong Wang; Zhihong Zheng; Yiqun Jiao; Benny J Chen; Phuong L Doan; Nelson J Chao; Yubin Kang
Journal:  Stem Cell Res Ther       Date:  2017-11-15       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.